News

Filter

1 to 9 of 10 results

FDA approves Baxter’s new treatment for rare form of hemophilia

FDA approves Baxter’s new treatment for rare form of hemophilia

25-10-2014

The US Food and Drug Administration on Friday approved Obizur (antihemophilic Factor [recombinant), porcine…

Baxter InternationalHematologyObizurPharmaceuticalRare diseasesUSA

Positive top-line Ph III results for Baxter’s BAX 855 in hemophilia A

Positive top-line Ph III results for Baxter’s BAX 855 in hemophilia A

21-08-2014

US drugmaker Baxter International has announced positive results from its Phase III pivotal clinical…

AdvateBAX 855Baxter InternationalHematologyPharmaceuticalRegulationResearch

Baxter opens its first state-of-the-art biologics facility in Asia

Baxter opens its first state-of-the-art biologics facility in Asia

08-08-2014

US drugmaker Baxter International has formally opened its S$370 million ($297 million) first advanced…

AdvateBaxter InternationalBiotechnologyEuropean Medicines AgencyHematologyHemophilia BProductionSingapore

Baxter buys AesRx, gaining rights to investigational SCD drug

Baxter buys AesRx, gaining rights to investigational SCD drug

10-07-2014

US drugmaker Baxter International said yesterday that it has acquired AesRx, a private US biopharmaceutical…

Aes-103AesRxBaxter InternationalBiotechnologyHematologyMergers & AcquisitionsRare diseasesUSA

Baxter’s BAX 111 meets Ph III primary efficacy endpoint for VWF patients

Baxter’s BAX 111 meets Ph III primary efficacy endpoint for VWF patients

17-04-2014

US health care company Baxter International as released encouraging top-line results from a Phase III…

BAX 111Baxter InternationalHematologyPharmaceuticalResearch

Baxter to acquire Chatham Therapeutics for $70 million

03-04-2014

USA-based Baxter International says it has agreed to acquire Chatham Therapeutics, a private biotechnology…

Baxter InternationalBiotechnologyChatham TherapeuticsHematologyMergers & Acquisitions

Baxter restructures deal with Xenetic Biosciences

31-01-2014

USA-based Baxter International has restructured its ongoing agreement with Xenetic Biosciences for the…

BAX 826Baxter InternationalHematologyLicensingPharmaceuticalResearchXenetic Biosciences

Baxter’s Feiba gains FDA approval for prophylactic treatment of hemophilia A and B

Baxter’s Feiba gains FDA approval for prophylactic treatment of hemophilia A and B

20-12-2013

US drugmaker Baxter International has received approval from the US Food and Drug Administration for…

Baxter InternationalFeibaHematologyPharmaceuticalRegulation

1 to 9 of 10 results

COMPANY SPOTLIGHT

Menarini

Back to top